Genenta Science S.p.A.
Clinical-stage developer of hematopoietic stem cell gene therapies for immuno-oncology.
GNTA | US
Overview
Corporate Details
- ISIN(s):
- US36870W1009
- LEI:
- Country:
- United States of America
- Address:
- OLGETTINA, NO. 58, 20132 MILAN
- Website:
- https://www.genenta.com/
Description
Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genenta Science S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
